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Caffeine, generally known as a stimulant of gastric acid secretion
(GAS), is a bitter-tasting compound that activates several taste
type 2 bitter receptors (TAS2Rs). TAS2Rs are expressed in the
mouth and in several extraoral sites, e.g., in the gastrointestinal
tract, in which their functional role still needs to be clarified. We
hypothesized that caffeine evokes effects on GAS by activation of
oral and gastric TAS2Rs and demonstrate that caffeine, when
administered encapsulated, stimulates GAS, whereas oral admin-
istration of a caffeine solution delays GAS in healthy human
subjects. Correlation analysis of data obtained from ingestion of
the caffeine solution revealed an association between the magni-
tude of the GAS response and the perceived bitterness, suggesting
a functional role of oral TAS2Rs in GAS. Expression of TAS2Rs, in-
cluding cognate TAS2Rs for caffeine, was shown in human gastric
epithelial cells of the corpus/fundus and in HGT-1 cells, a model for
the study of GAS. In HGT-1 cells, various bitter compounds as well
as caffeine stimulated proton secretion, whereby the caffeine-
evoked effect was (i) shown to depend on one of its cognate receptor,
TAS2R43, and adenylyl cyclase; and (ii) reduced by homoeriodictyol
(HED), a known inhibitor of caffeine’s bitter taste. This inhibitory
effect of HED on caffeine-induced GAS was verified in healthy
human subjects. These findings (i) demonstrate that bitter taste
receptors in the stomach and the oral cavity are involved in the
regulation of GAS and (ii) suggest that bitter tastants and bitter-
masking compounds could be potentially useful therapeutics to reg-
ulate gastric pH.
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Caffeine, a bitter-tasting methylxanthine alkaloid present incoffee and tea beverages, is the world’s most frequently con-
sumed psychoactive drug that functions as a stimulant of the au-
tonomic and central nervous system (CNS) (1). It is also an
activator of gastric acid secretion (GAS) (2–5). Although part of
caffeine’s effect appears to be mediated by antagonizing aden-
osine receptors and inhibition of phosphodiesterases (PDEs) (1),
the observation that several other bitter-tasting compounds, such
as denatonium benzoate (6); hop-derived beer bitter acids; α-, β-,
iso-α-acids (7); and catechin and procyanidin B2 (8) cause gastrin
release (6) or GAS (7, 8) indicates that bitter substance-evoked
chemosensory mechanisms may be involved. Chemosensation
potentially plays a role at three sites to regulate GAS: (i) bitter
substances could excite oral taste cells and mediate their effects
through cephalic regulation of gut physiology (9) or (ii) a bitter
compound could also act in the gut through induction of gastrin
and/or histamine release from enteroendocrine cells and/or (iii) by
modulating acid production in GAS-producing parietal cells (10).
Bitter tastants elicit bitterness through a family of oral taste
type 2 bitter receptors (TAS2Rs) (11). Humans express approxi-
mately 25 TAS2 receptors, of which five TAS2Rs, TAS2Rs 7, 10,
14, 43, and 46, can be activated by caffeine (12). In addition to
the mouth, TAS2Rs have also been identified in nongustatory
tissues, including airway epithelia (13), brain (14), intestinal cells
(15, 16), and the gastric epithelia of rats and mice (17, 18). Be-
yond their chemosensory function, extraoral TAS2Rs are in-
volved in nonsensory processes to expel or neutralize toxins in
the upper and lower airways as well as in the gastrointestinal
tract (19). Furthermore, the TAS2R pathway in the gut is in-
volved in the regulation of food intake, digestion, and satiation
(15, 16, 20, 21). Whereas, in the stomach, the endocrine effect of
bitter substances on ghrelin secretion has been well described
(20), a bitter compound-mediated exocrine function on acid
production in parietal cells had not yet been discovered to our
knowledge. Parietal cells can be activated by histamine or ace-
tylcholine binding to their cognate histamine H2 or acetylcholine
M3 receptors (22). Activation of these receptors results, either
by Gs- and adenylyl cyclase/cAMP- or by Gq- and phospholipase
C (PLC)/IP3/Ca
2+-dependent pathways, in the activation of the
H+,K+-ATPase, which pumps protons into the stomach lumen (22).
In taste cells located on the tongue, the signaling cascade of TAS2Rs
also includes a cAMP-dependent and a PLCβ2/IP3/Ca2+-dependent
pathway (23). Initiation of the latter major pathway leads to cal-
cium release from intracellular compartments, which in turn
activates transient receptor potential M5 ion channels. These
channels mediate an influx of sodium ions and membrane de-
polarization (23), leading to ATP release and bitter perception.
The α-subunit of gustducin has been described to stimulate
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PDEs, resulting in low cAMP levels and PKA activities, which
keep the IP3 type 3 receptor hypophosphorylated and sensitized
(24). Therefore, the tonic activity of α-gustducin regulates taste
cell responsivity. Transducin, a similar G protein also present in
taste cells, can replace the function of α-gustducin (25, 26).
TAS2R-expressing cells in the gastrointestinal tract have been
reported to coexpress the downstream taste signaling components,
suggesting that similar signal transduction pathways could also
mediate gastrointestinal physiology (27). However, the detailed
signal transduction pathways in extraoral chemosensitive cells
are yet unknown.
This study investigated whether gastric and oral TAS2Rs
contribute to the regulation of caffeine-induced mechanisms of
GAS in humans. To study this hypothesis, the effect of caffeine
on GAS was investigated in a human intervention trial, taking
into account taste receptor activation in the mouth and the stom-
ach. The underlying gastric mechanisms were studied by TAS2R
expression analysis and by means of the validated HGT-1 cell cul-
ture model, which maintains the relevant characteristics of human
parietal cells (28, 29).
Results
Oral Bitter Perception Reduces GAS in Human Subjects. Real-time
gastric pH measurements were performed after caffeine adminis-
tration in human subjects by means of Heidelberg pH diagnostic
capsules (29–32). Heidelberg pH capsules are used to determine
gastric acid secretory ability under conditions simulating the in-
gestion of food or beverages by means of radiotelemetry. For the
measurements, overnight-fasted subjects swallow the pH capsule,
followed by a saturated sodium bicarbonate solution. Ingestion of
the bicarbonate solution triggers an increase in stomach pH and
a subsequent attempt by the parietal cells to reestablish acidity.
The impact of foods or beverages on the reacidification time can
be analyzed by administration of the test material before or after
the pH challenge. In this study, subjects swallowed a caffeine
solution with or without a bitter-masking compound, homoer-
iodictyol (HED) (33, 34) 5 min after or 25 min before the bi-
carbonate challenge. Reacidification time was measured for
three distinct delivery protocols (1–3), each of which assesses
different sites of TAS2R activation (Fig. 1A). The subjects un-
derwent the following interventions in 11 consecutive study site
visits (Fig. 1B): For the first 8 visits, test compounds were ad-
ministered 5 min after the bicarbonate solution. In delivery
protocol (1), subjects drank 125 mL water, a caffeine solution
(37.5, 75, or 150 mg caffeine in 125 mL water) with or without
30 mg HED, or an HED solution (30 mg HED in 125 mL water),
thereby stimulating oral and gastric TAS2Rs (Fig. 1B). For de-
livery protocols 2 and 3, a dose of 150 mg caffeine was adminis-
tered along with 125 mL water, either encapsulated to selectively
stimulate gastric TAS2Rs, or as a sip-and-spit solution to activate
only oral TAS2Rs, respectively (Fig. 1B).
During the final three visits, subjects were asked to drink
125 mL water or 150 mg caffeine with or without 30 mg HED in
125 mL water (delivery protocol 2) 25 min before the bicarbonate
challenge to evaluate the effect of administration time. The in-
tervention time of 25 min was chosen according to previous
publications that demonstrated that caffeine starts to stimulate
gastric acid after 30 min (2, 5).
Drinking the volume water control solution 5 min after the
bicarbonate challenge resulted in a mean reacidification time of
23 ± 1 min (individual representative gastrogram shown in Fig.
1C). Oral application of caffeine by sip-and-spit or drinking led
to prolongations (P < 0.05) of reacidification time by delta
reacidification time values (reacidification timetest compound −
reacidification timewater) of 20 ± 6 min and 8 ± 2 min, re-
spectively, compared with administration of a volume water
control solution, indicating a delay of GAS (Fig. 1D). Stimula-
tion of gastric sites only by encapsulated caffeine resulted in a
shorter delta reacidification time of 5 ± 3 min relative to sip-and-
spit administration (P < 0.05; Fig. 1 C and D). Individual gas-
trograms were quantified by determining the slope after the
onset of reacidification. A higher slope indicates that, when
reacidification has started, the gastric pH returns to its initial pH
faster. The slope of the gastrogram (relative to water control)
obtained after administration of encapsulated caffeine was
higher (0.20 ± 0.16 pH units per min) compared with the slope
calculated after drinking (−0.20 ± 0.10 pH units per min) and
sip-and-spit intervention (−0.39 ± 0.05 pH units per min),
whereby stimulation of oral receptors occurred (Fig. 1E). To
extend the time period over which the effect of caffeine on GAS
could be measured, we repeated the experiments with encapsu-
lated caffeine administered with 125 mL water 25 min before the
alkaline challenge. This intervention allows gastric pH changes
to be recorded over a time period of 25 min to approximately
85 min after caffeine administration and revealed a stimulation
of GAS, indicated by a reduced delta reacidification time of
−23 ± 4 min by caffeine (Fig. 2B) compared with control treat-
ment (empty capsule plus 125 mL water reacidification time,
41 ± 4 min; P < 0.01).
HED Reduces the Caffeine-Evoked Effects on GAS in Human Subjects.
To determine if TAS2R bitter-taste receptors mediate the effect
of caffeine on GAS, 125 mL water containing 150 mg caffeine
and/or 30 mg of the bitter-masking compound HED (33, 34)
were swallowed 5 min after the alkaline challenge (delivery
protocol 1). Administration of HED alone resulted in a reac-
idification time of 21 ± 2 min, comparable to that of water (24 ±
1 min) as volume control.
Unexpectedly, concomitant administration of HED and caf-
feine resulted in accelerated gastric emptying in 4 of 10 subjects,
as indicated by passing of the Heidelberg capsule into the duo-
denum before complete reacidification. The same effect was
observed in 2 of 10 subjects after drinking a solution of 30 mg
HED dissolved in 125 mL water. When HED and caffeine were
administered encapsulated (delivery protocol 2), reacidification
times could be analyzed in only six subjects, as four subjects
demonstrated accelerated gastric emptying as seen after oral and
gastric delivery (protocol 1). These results raised the question
whether the bitter-masking compound HED promotes gastric
motility by stimulating gastric relaxation. Experiments using
strips of dissections of human stomach biopsy specimens
revealed that treatment with 1 mM HED in an organ bath
induced a maximum relaxation after 40 min, with mean tension
values of 45.4 ± 6.7%, compared with water control values of
107 ± 5.7% (Fig. S1 A and B).
In those subjects who were subjected to delivery protocol
1 and did not respond with accelerated gastric emptying, HED
largely reversed the effects of caffeine on reacidifcation time:
whereas drinking of the caffeine solution 5 min after alkaline
challenge resulted in a delta reacidification time of 8 ± 2 min,
concomitant caffeine and HED administration revealed a mean
value of 1 ± 1 min (Fig. 2 A and B), but showed no effect on the
slope of the gastrogram (Fig. 2C). In contrast, gastric adminis-
tration of encapsulated caffeine 25 min before alkaline challenge
(delivery protocol 2) induced GAS compared with administration
of water, resulting in a delta reacidification time of −23 ± 4 min
(Fig. 2 D and E). Although the reversing effect of HED on the
caffeine-mediated reacidification shown in Fig. 2D did not reach
statistical significance in terms of reacidification time (P = 0.087;
Fig. 2E), concomitant application of HED and caffeine reduced
the slope of the gastrogram compared with caffeine administra-
tion, with mean respective values of 0.18 ± 0.13 pH units per min
and 0.64 ± 0.26 pH units per min (P < 0.05; Fig. 2F).
The potent attenuation of caffeine’s effects on GAS by the
bitter-masking agent HED suggests that TAS2Rs are critically
involved in caffeine’s action in the mouth and the stomach.
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Sensory Evaluation. To verify that the subjects were capable of
sensing caffeine bitterness, the bitter recognition threshold of the
same subjects who underwent the gastric pH measurements was
determined by means of a threshold test, which yielded a result
of 117 ± 44 mg/L for caffeine. In addition, the subjects rated the
bitterness of 1,200 mg/L caffeine in the absence or presence of
240 mg/L HED in a blinded duo sensory test and confirmed the
bitter-masking effect of HED reported by Ley et al. (33):
Whereas the mean bitterness rating (±SD) for the caffeine so-
lution was 7.5 ± 1.7, ratings for caffeine plus HED revealed
mean values of 5.8 ± 1.9, corresponding to a −20 ± 8% reduction
of caffeine-mediated bitterness by HED (Fig. S2A). The subjects’
caffeine bitterness scores correlated with reacidification time
(correlation coefficient, 0.66; P = 0.03; n = 10; Fig. S2 B and C)
after caffeine administration by drinking (delivery protocol 1,
5 min after alkaline challenge), as well as with reacidification
time after caffeine plus HED administered by drinking (corre-
lation coefficient, 0.89; P < 0.05; n = 6; 5 min after alkaline
challenge). No statistically significant correlation between bitter
intensity rating and reacidification time was calculated after ad-
ministration of encapsulated caffeine (delivery protocol 1; P > 0.05).
TAS2R Expression in HGT-1 Cells and Human Gastric Tissue. The
mRNA expression of 25 human TAS2Rs in the HGT-1 cell line
was investigated by quantitative RT-PCR (RT-qPCR) studies.
The genes for the five TAS2Rs known to be activated by caf-
feine, TAS2Rs 7, 10, 14, 43, and 46 (12), as well as several other
TAS2R genes, are expressed at similar or even higher levels than
the M3 acetylcholine receptor CHRM3 gene, a major regulator
of GAS (Table 1). Although TAS2R5 and TAS2R14 are the most
highly expressed TAS2Rs, TAS2R8, 45, and 60 mRNAs were not
found in HGT-1 cells. HGT-1 cells also express mRNAs for
TAS2R downstream signaling proteins PLCβ2, transducin
(GNAT2), and α-gustducin (GNAT3) (11, 23) (Table 1). Like
the parietal cell line HGT-1, the human gastric epithelium
contains transcripts for the five cognate caffeine bitter receptors
TAS2R7, TAS2R10, TAS2R14, TAS2R43 and TAS2R46 at
levels similar to those of the M3 acetylcholine receptor, with ratios
relative to that receptor of 0.76 ± 0.039, 0.97 ± 0.190, 1.16 ± 0.025,
0.62 ± 0.017, and 0.83 ± 0.071, respectively.
The presence of the broadly tuned, caffeine-sensitive TAS2R10
receptor (12) in the gastric epithelium was confirmed by immu-
nohistochemical staining of stomach surgical specimens from the
antrum and fundus/corpus region. The specificity of the TAS2R10
antibody was verified in transiently transfected HEK-293T cells
(Fig. S3). In gastric mucosa, cell types were identified by H&E
staining (Figs. S4 and S5). Parietal cells are localized in the glands
of gastric fundus and body, and are scattered in the middle and, to
a lesser extent, in the bottom part of the mucosa (Fig. S4). They
are characterized by broad pink cytoplasms. Chief cells stain with
basophilic cytoplasm and are mainly located in the bottom parts
of the mucosa (Fig. 3A and Fig. S4). Localization of TAS2R10
staining was confined to parietal cells and to gastric chief cells in
the fundus/corpus, showing strong cytoplasmic granular re-
activity (Fig. 3 A, a and b). Staining of glandular cells in the
gastric antrum was faint, consisting of very weak cytoplasmic and
focal intermediate membranous reaction (Fig. 3 A, e and f). In
contrast, mucus-producing foveolar cells in the fundus/corpus
(Fig. 3 A, a and b) and antrum (Fig. 3 A, e and f) did not show
Fig. 1. Results of the gastric pH measurements demonstrate that the effect
of caffeine (CAF) on reacidification time is influenced by the type of ad-
ministration. (A) Overview of the different administration types in the hu-
man intervention trial. (B) Overview of the study procedure. (C) Gastrograms
of different Heidelberg capsule measurements from one test subject com-
bined in one graphic show that 150 mg caffeine diluted or administered
with 125 mL water (blue line) administered by sip and spit (3) prolongs the
reacidification time (i.e., time until the original pH is reached again) more
than administration via drinking (2) or in encapsulated form (1). (D) Delta
reacidification time of gastrograms show that sip-and-spit administration
resulted in the highest prolongation of reacidification time compared with
gastric and gastric plus oral administration. (E) Delta slope of the gastro-
grams indicate that encapsulated administration (gastric delivery) strongly
stimulate GAS when reacidification has started. Data are displayed as
mean ± SEM, n = 5–10; one-way ANOVA with Holm–Sídák post hoc test;
significant (P < 0.05) differences are indicated by distinct letters [*P < 0.05,
significant vs. water control (basal = 0) tested with paired Student t test].
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expression of TAS2R10. Blocking experiments showed a clear
staining reduction (Fig. 3 A, c, d, g, and h), supporting the epi-
tope specificity of the antiserum. Like TAS2R10, the down-
stream signaling molecule transducin was localized in parietal
and chief cells of the corpus/fundus, indicating that TAS2R10
and transducin are coexpressed in a substantial fraction of these
cells. In addition, transducin immunoreactivity is present in the
membranes of foveolar cells in gastric fundus/corpus (Fig. 3 A, i
and j), but not in the antrum (Fig. 3 A, m and n). TAS2R10 and
transducin expression was also detected in almost all HGT-1 cells
(Fig. 3B), indicating that both proteins are coexpressed. Together,
our data show that the mRNAs for caffeine’s cognate TAS2Rs
and at least one bitter receptor polypeptide are present in the
human stomach and HGT-1 cells.
Effect of Bitter and Bitter-Masking Compounds on Proton Secretion in
HGT-1 Cells.Following our hypothesis that bitter compounds induce
mechanisms of GAS via TAS2Rs, various bitter compounds, such
as theobromine, tannic acid, yohimbine, denatonium benzoate,
sodium benzoate, and aristolochic acid were tested and verified
for their stimulating effects on proton secretion in HGT-1 cells
(Fig. 4A). The concentrations of the tested compounds were
chosen based on preliminary experiments to elicit the strongest
effect on proton secretion without impairing cellular viability [>90%
compared with nontreated controls (100%)]. The responses were
similar in magnitude, or even more pronounced, compared with
those elicited by histamine, a major activator of proton secretion in
parietal cells (10). These responses to bitter compounds indicate
that several TAS2Rs could be activated in HGT-1 cells. Treatment
of HGT-1 cells with 0.3–3,000 μM caffeine increased proton se-
cretion, with 3,000 μM caffeine showing the highest effect (Fig. S6 A
and B). The bitter-masking compounds HED and eriodictyol (ED),
which have been described to reduce the bitter taste of caffeine in
human sensory panels (33, 34), also reduced the caffeine-evoked
proton secretion in HGT-1 cells (Fig. 4B and Fig. S6C).
Antagonistic or Agonistic Effect of HED and ED on TAS2Rs-Induced
Ca2+ Mobilization in HEK-293T Cells. To identify the TAS2Rs that
are targeted by HED and its structural analog ED, Ca2+-mobi-
lization in the presence of these compounds by transiently
transfected HEK-293T cells was analyzed with or without cos-
timulation with specific agonists of TAS2Rs (12). HED and ED
were identified as agonists for TAS2R14 and as antagonists for
TAS2Rs 43, 20, and 50 (Table S1). HED is also an antagonist for
TAS2R31 (Table S1). As TAS2R43 can be activated by caffeine
(12), the effect of caffeine and HED was further investigated in
HEK-293T cells transiently transfected with TAS2R43. TAS2R43
in these cells was then activated by aristolochic acid or caffeine for
the performance of calcium imaging experiments in the presence
of increasing concentrations (0.03−30 μM) of HED and ED. Both
compounds reduced TAS2R43 responses to aristolochic acid or
caffeine (Fig. 4C).
Caffeine-Induced Proton Secretion Is Reduced in TAS2R43 KO HGT-1
Cells. To determine whether TAS2R43 is involved in mechanisms
of caffeine-induced GAS, a homozygous 13-bp deletion in the
TAS2R43 gene (Fig. S7) of HGT-1 cells was induced by using a
CRISPR-Cas9 CD4-vector (i.e., TAS2R43-KO). As negative
control (NC), HGT-1 cells were treated in parallel with the same
vector containing a nontargeting scrambled guide RNA (gRNA).
Off-target effects of the transfected gRNA were excluded by a whole-
genome sequencing analysis. The stimulating effect of caffeine and
the TAS2R43 agonist aristolochic acid on proton secretion in
HGT-1 cells was substantially reduced in TAS2R43-KO cells com-
pared with NC cells (Fig. 4D). These data demonstrate that TAS2R43
is involved in caffeine’s action on proton secretion in HGT-1 cells.
Considering that caffeine’s effect on proton secretion in HGT-1
cells is sensitive to TAS2R43 and HED, and that TAS2R43 is
blocked by HED in TAS2R43-transfected HEK-293T cells, the
data strongly suggest that caffeine mediates its effect through at
least one TAS2Rs (TAS2R43) if not more.
Fig. 2. Addition of HED reduces the caffeine-evoked effects on reacidification time or the slope in gastric pH measurements via administration by drinking
150 mg caffeine (CAF) with or without 30 mg HED dissolved in 125 mL water (A–C) or by encapsulated test compounds in combination with 125 mL water
25 min before alkaline challenge (D–F). (A and D) Gastrograms of Heidelberg capsule measurements according to the three different delivery protocols from
one test subject are presented in one graphic. (B and E) Delta reacidification time of gastric pH measurements in subjects after consumption of CAF or CAF
plus HED (basal = 0). (C and F) Delta slope of gastric pH measurements in subjects after consumption of CAF or CAF plus HED (basal = 0). Data are displayed as
mean ± SEM: (B and C) CAF, n = 10; CAF plus HED, n = 6; (E and F) CAF, n = 7; CAF plus HED, n = 6 (*P < 0.05 and **P < 0.01 indicate significant differences by
Student’s t test).
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Effect of Pharmacological Blockers on Caffeine-Induced Proton Secretion.
Caffeine-evoked proton secretion was reduced by neither the
PLCβ2 inhibitor U73122 nor the IP3 inhibitor neomycin (Fig.
4E). In contrast, it was reduced by the adenylyl cyclase inhibitor
NKY80 (−22.5 ± 7.4%; P < 0.01), suggesting that cAMP but not
Ca2+ signaling is involved in TAS2R-mediated regulation of acid
secretion in HGT-1 cells.
Effect of Caffeine and HED on cAMP Levels in HGT-1 Cells. To confirm
that adenylyl cyclase mediates proton secretion in HGT-1 cells
via caffeine-dependent TAS2R stimulation, intracellular cAMP
levels were determined in response to treatment with caffeine
and HED (Fig. 4F). Treatment of HGT-1 cells for 10 min with
3.0 mM caffeine increased cAMP levels by 12 ± 4.6% (P < 0.05)
in comparison with the treatment with DMEM (control, 100 ±
2.0%). However, coapplication of caffeine and HED (83.3 ± 2.7%;
P < 0.01) and HED alone (84.9 ± 5.1%; P < 0.05) reduced cAMP
levels in HGT-1 cells. Treatment with forskolin, a stimulator of
adenylyl cyclase, increased cAMP levels to 131 ± 10.3% (P < 0.05)
in HGT-1 cells in comparison with treatment with the solvent
control ethanol (i.e., EtOH). These observations confirm that caf-
feine activates TAS2Rs signaling through changes in cAMP levels.
Discussion
Acid secretion in the stomach is a fundamental process that is
finely regulated at different levels. Initial activation of GAS is
regulated by the CNS when food is smelled and tasted (10, 35).
When food enters the stomach, mechanical or chemical recep-
tors (i) initiate GAS via activation of afferent/efferent fibers
connected to the CNS, (ii) stimulate the gastrin-producing G
cells or the histamine-producing enterochromaffin-like cells,
or (iii) directly stimulate the HCl-producing parietal cells. Caf-
feine stimulates GAS, and, so far, it has been assumed that it acts
via inhibition of PDE or by antagonizing adenosine receptors
in gastric parietal cells (1). As caffeine activates five of the
25 human TAS2Rs (12), we hypothesized that its bitterness
also contributes to its stimulating effect on GAS via activation
of TAS2Rs.
First, we found that oral consumption of caffeine delayed
GAS in healthy subjects, whereas caffeine that was administered
encapsulated, being released in the stomach, accelerated this
process compared with oral administration. The delay induced
by oral caffeine presentation might be explained by findings
reported by McMullen et al. (36). They demonstrated that caffeine
in a coffee drink accelerated the heart rate without increasing the
vascular tonus in comparison with caffeine administered encapsu-
lated concomitantly to a decaffeinated coffee drink. The increase in
heart rate was likely induced by vagal withdrawal instead of sym-
pathetic activation. This finding is important, considering that the
cephalic-phase response during digestion is thought to activate the
vagus nerve to enhance digestion (36). The study of McMullen et al.
(36) along with the present results suggest that orally sensed caf-
feine elicits vagal withdrawal that would reduce rather than enhance
the digestive capacity, for example by delaying GAS. An expla-
nation why the delaying effect of caffeine has not been discussed
earlier might be that most of the previous studies investigating
the effect of caffeine on GAS used gavages to bypass oral cavity
receptors (2, 3, 5) and therefore did not take into account an
inhibitory effect of caffeine on GAS by oral perception. Fur-
thermore, we demonstrated that TAS2R bitter receptors in the
stomach are involved in the caffeine-induced secretion of gastric
acid. This conclusion is based on the observation that the bitter-
masking compound HED similarly reduced caffeine’s bitterness
as well its effects on GAS evoked by combined oral/gastric or
gastric-only caffeine application. The finding that concomitant
oral ingestion of caffeine and HED accelerated passing of the
Heidelberg capsule into the duodenum in 4 of 10 subjects
compared with caffeine administration indicates that HED might
induce gastric emptying. This hypothesis has been verified by
measuring the effect of HED on gastric motility in strips of
stomach dissections in an organ bath. Avau et al. (37) demonstrated
that bitter compounds such as denatonium benzoate increased
contractility in gastric strips of mice and caused an impairment of
gastric relaxation after intragastric infusion. Whether a bitter-
masking compound has opposite effects by causing gastric re-
laxation is an open question. The data presented here did not
show any effects of HED on gastric secretion in humans, nor on
proton secretion in HGT-1 cells at the concentrations tested.
However, HED induced gastric relaxation, indicating physio-
logical targets other than GAS.
To confirm that caffeine induces GAS via gastric TAS2Rs, we
demonstrated that the mRNA of 22 of 25 TAS2Rs as well as
transducin is present in HGT-1 cells, and that the five TAS2Rs
that can be activated by caffeine are present in the stomach
mucosa. These findings were corroborated by immunohisto-
chemical detection of TAS2R10 and transducin in different gastric
cell types for which useful antisera were available. So far, to our
knowledge, only one validated antibody against human TAS2R38
(38) is known. Neither caffeine nor HED bind to TAS2R38. An
antibody against TAS2R43 (OSR00171W; Thermo Fisher Scien-
tific) was tested. Unfortunately, during validation in transfected
HEK-239T cells, this antibody turned out to be unspecific. Nev-
ertheless, we could demonstrate data for the validation of an an-
tibody targeting TAS2R10 (Fig. S3) and show the expression of
TAS2R10 on a protein level in gastric mucosa and HGT-1 cells.
Table 1. mRNA expression of TAS2Rs in HGT-1 cells normalized
to the expression of the acetylcholine receptor (CHRM3)
Receptor/gene
HGT-1
Mean SEM
CHRM3 1.00 0.035
TAS2R1 0.20 0.050
TAS2R3 9.87 0.848
TAS2R4 5.66 0.765
TAS2R5 12.08 0.822
TAS2R7 0.32 0.073
TAS2R8 No specific product
TAS2R9* 0.12 0.019
TAS2R10 0.97 0.100
TAS2R13 1.69 0.144
TAS2R14 12.39 1.347
TAS2R16 0.71 0.239
TAS2R19 4.40 0.678
TAS2R20 9.09 1.139
TAS2R30 8.02 0.717
TAS2R31 4.00 1.767
TAS2R38 0.14 0.045
TAS2R39 3.64 0.807
TAS2R40 0.51 0.052
TAS2R41 0.66 0.143
TAS2R42 2.24 0.444
TAS2R43 6.47 0.316
TAS2R45 Not detected
TAS2R46 2.59 0.421
TAS2R50 2.91 0.290
TAS2R60 No specific product
PLCB2 2.47 0.110
GNAT2 7.16 0.557
GNAT3 0.04 0.014
Data are shown as mean ± SEM; n = 3–4 biological replicates, tr = 3 tech-
nical replicates. The mRNA of TAS2Rs is similarly or even more highly
expressed compared with the mRNA of CHRM3 in HGT-1 cells.
*In one of three replicates, no product was detected.
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As TAS2R10 was highly expressed in parietal cells, as detected
by immunohistological staining, we focused on the cellular
mechanisms in HGT-1 cells, which exhibit the characteristics of
parietal cells (28, 29). Nevertheless, we cannot exclude that other
cell types or gastrointestinal hormones may have contributed to
the detected effects in the human intervention study. We dem-
onstrated here that the bitter-masking agent HED reduced the
stimulatory effect of caffeine on proton secretion in healthy
subjects and in HGT-1 cells. As TAS2R43 is the only one of the
five TAS2Rs that can be activated by caffeine and antagonized
by HED, we also performed a CRISPR-Cas9 approach to knock
out TAS2R43 in HGT-1 cells. In these TAS2R43-KO cells, the
effect of caffeine on proton secretion was reduced in comparison
with control cells. To further confirm our hypothesis that
TAS2Rs are involved in mechanisms regulating GAS, TAS2R43
was transiently transfected into HEK-293T cells, which do not
normally express any TAS2Rs. In this cell model, we demon-
strated that HED antagonized caffeine-stimulated responses in
TAS2R43-transfected cells. These results strongly indicate that
TAS2R43 is involved in the proton secretory effect of caffeine.
Nevertheless, involvement of other TAS2Rs or signaling path-
ways, such as adenosine receptors, or PDE inhibition cannot
be excluded.
HED is also an agonist for TAS2R14, which is highly
expressed in HGT-1 cells. The interaction of agonistic and an-
tagonistic effects on TAS2Rs and the further activation of
downstream signaling pathways seem highly complex, and not
every TAS2R might be connected to the same downstream sig-
naling cascade. One downstream signal for the induction of
proton secretion is cAMP. Here, we show that caffeine increased
cAMP levels in HGT-1 cells, an effect that was inhibited by
HED. HED itself reduced the cAMP level in HGT-1 cells, but
did not affect proton secretion in HGT-1 cells. Therefore, it
remains unclear whether or which signaling pathways are af-
fected by HED. Caffeine signaling via cAMP is supported by the
fact that the adenylyl cyclase inhibitor NKY80 reduced the
caffeine-evoked stimulation of proton secretion. Caffeine-
induced activation of PLCβ2 and IP3 signaling can be excluded
by the failure of the specific inhibitors U73122 (PLCβ2) and
neomycin (IP3) to reduce proton secretion. Experiments in
which caffeine and HED were tested in combination with the
inhibitors showed no difference in proton secretion in compari-
son with caffeine and HED tested alone. That leaves the ques-
tion of how caffeine can stimulate GAS via TAS2Rs. So far, only
for sweet and glutamate taste receptors (TAS1R1/3) has an in-
crease of cAMP levels via activation of adenylyl cyclase been
demonstrated (39). The signaling cascade of bitter taste recep-
tors has been proposed to reduce cAMP levels by activation of
PDE via α-gustducin or transducin (23, 26, 40).
Based on our results, we hypothesize that bitter perception of
caffeine in the mouth generates a signal of aversion, which leads,
via vagal withdrawal, to inhibition of GAS (41). However, when
bitter compounds reach the stomach, increased GAS could aid
degradation or removal of the potential toxins. This hypothesis is
Fig. 3. (A, a–p) Immunochemical localization of TAS2R10 and GNAT2 in (A) gastric tissue and (B) HGT-1 cells with and without preincubation with a blocking
peptide. (a) In the gastric corpus/fundus, cytoplasmic reactivity of TAS2R10 in parietal and chief cells (one arrow) was detected whereas foveolar cells were
negative (two arrows). Detail (b) shows parietal and chief cells. In the gastric antrum (e and f), very faint cytoplasmic and focal membranous reactivity of
TAS2R10 in glandular cells was detected (one arrow). Foveolar cells are negative (two arrows). (f) Detail showing glandular cells. GNAT2 was localized in the
gastric fundus (i and j) parietal and chief cells (one arrow, j). Foveolar cells demonstrate membranous staining (two arrows, j). (m and n) In gastric antrum,
membranous reactivity of GNAT2 in glandular cells (one arrow,m and n) was detected whereas foveolar cells were negative (two arrows,m). (c, d, g, h, k, l, o,
and p) Corresponding negative controls. (B) Staining of HGT-1 cells with TAS2R10 and GNAT2 antisera (green) with and without specific blocking peptide and
cell-surface labeling with con A (red).
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supported by previous studies demonstrating that extraoral
TAS2Rs are probably involved in defense mechanisms in other
parts of the gastrointestinal tract and form a “chemofensor
complex” (18, 19, 42). The differential effect of site-specific
TAS2R activation on GAS we demonstrated has not been
reported so far to our knowledge and warrants further investi-
gations. The expression of TAS2Rs in murine goblet cells (18), a
cell type that secretes mucus to protect the epithelium, and the
fact that bitter substances increase anion transport and fluid
secretion in human and rat colon tissue (42), indicate defense-
related functions of bitter taste receptors. Furthermore, in in-
testinal cells, Jeon et al. (43) identified a TAS2R38-dependent
activation of the ATP-binding cassette B1 (ABCB1) via phen-
ylthiocarbamide (PTC). As ABCB1 is an efflux transporter lo-
cated on the apical membrane of intestinal epithelial cells to
limit absorption of toxic substrates contained in food, TAS2R
signaling has been assumed to limit the absorption of potentially
hazardous bitter-tasting substances in the intestine (43).
Our results clearly demonstrate that the route of application
of caffeine determines its effects on GAS, and suggest that other
bitter tastants and bitter-masking compounds are also potentially
useful therapeutics to regulate gastric pH. Finally, our results
support the pleiotropic functions of taste receptors far beyond
their role in taste.
Materials and Methods
Chemicals. The sodium salt of HED (3′-methoxy-4′,5,7-trihydroxyflavanone)
and ED was provided by Symrise. All other chemicals were obtained from
Sigma-Aldrich unless stated otherwise.
Identification of the Influence of Bitter Taste on GAS in Vivo. The human in-
tervention study was designed as a single-blinded, randomized, controlled,
longitudinal trial and was performed in accordance with good clinical prac-
tice guidelines and the Declaration of Helsinki. The experimental protocol
was reviewed by the ethics committee of the city of Vienna (registration no.
EK 13–180–VK_NZ), and the study has been registered at ClinicalTrials.gov
(ID code NCT02372188). The subjects provided written informed consent
after they had been given a detailed oral and written description of the
study. The 13 healthy test subjects had no gastrointestinal complaints, were
nonsmokers, did not take antibiotics for 2 mo before the test, and were
between 21 and 32 y of age, with a body mass index between 19 and 25 kg/m2.
Helicobacter pylori infection was excluded by an immunochromatographic rapid
capillary blood test (Diagnostik Nord). Average habitual caffeine consumption
was 125 mg/d and determined by a food frequency questionnaire of caffeine-
containing food and beverages. The Heidelberg capsule measurements
were carried out at the Department of Nutritional and Physiological
Fig. 4. Bitter tastants increase proton secretion in human gastric cells. Studies were performed with cultured HGT-1 cells loaded with the pH-sensitive
fluorescent dye SNARF-1-AM and treated with test compounds for 10 min (A, B, and D). Results are presented as the IPX. A lower IPX value indicates increased
proton secretion. Data displayed as mean IPX ± SEM. (A) IPX of HGT-1 cells after treatment with histamine (HIS; 1 mM), yohimbine (YO; 30 μM), denatonium
benzoate (DB; 30 μM), caffeine (CAF; 3.0 mM), theobromine (TH; 0.3 mM), tannic acid (TA; 3 μM), aristolochic acid (AA; 0.3 μM), and sodium benzoate (SB;
3.0 mM) in comparison with untreated cells (i.e., control; marked as “C”) or 0.1% DMSO-treated cells [solvent control for yohimbine; n = 3–16; six technical
replicates (tr)]. (B) Coadministration of HED reduces the stimulating effect of caffeine on proton secretion (n = 4–37; tr = 6). (C) Inhibition curves of
TAS2R43 assessed through calcium imaging experiments in transfected HEK-293T cells. Cells were costimulated with 0.03 μM aristolochic acid (Arist. Ac.) or
caffeine 1 mM and increasing concentrations of the inhibitors HED or ED. Caffeine and aristolochic response amplitudes (ΔF/F0) were 0.14 and 0.39, re-
spectively. Concentrations were chosen based on preliminary experiments to elicit the strongest effect. (D) IPX of HGT-1 cells transfected with nontargeting
gRNA (NC) or HGT-1 cells with KO of TAS2R43 by CRISPR-Cas9 deletion treated with histamine (HIS; 1 mM), aristolochic acid (AA; 0.3 μM), caffeine (CAF;
3.0 mM), or 3.0 mM caffeine and 0.3 mM HED (n = 5–6; tr = 6). (E) Percentage inhibition of 3 mM caffeine effect on IPX of HGT-1 cells in comparison after
treatment with 3 mM caffeine in combination with 0.3 mM HED, 5 μM U73122, 100 μM neomycin, or 30 μM NKY80 (n = 3–6; tr = 6). (F) cAMP concentration
in HGT-1 cells after 10 min treatment with 3 mM caffeine, 0.3 mM HED, or in combination in comparison with DMEM, EtOH 0.1%, or forskolin 10 μM (n = 4;
tr = 2). (A–E) Data presented as mean ± SEM. (C) Data presented as mean ± SD. Statistics: (A, B, and F) one-way ANOVA with Holm–Sídák post hoc test
(F) vs. DMEM and (A and C–F) Student’s t test. Significant (P < 0.05) differences are indicated by letters or as follows: ###P < 0.001 vs. DMSO 0.1%; ***P < 0.001,
**P < 0.01, and *P < 0.05.
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Chemistry, University of Vienna, Austria. At each visit, subjects were sub-
jected to one treatment, meaning that subjects who took part in all ad-
ministration types and treatments completed 11 visits (Fig. 1B). Before the
intervention, the trial subjects had to fast from food and liquid for 10 h. For
the noninvasive measurement of gastric pH, the Heidelberg Detection Sys-
tem (Heidelberg Medical) was applied as described before (29, 30). When
the subject arrived in the morning, the pH capsule was prepared by activa-
tion for 5 min in a sterile 0.9 NaCl solution and, as indicated by the Hei-
delberg Detection System software, the capsule was calibrated at pH 1 and
pH 7. After calibration, the capsule was swallowed by the subject. When a
pH of approximately 1–2 was stable over a period of 3 min, a stable position
of the capsule in the stomach was considered to have been achieved. During
the measurement, the subjects had to lie down on their left side to make
sure that the capsule remained in the stomach. Each trial started with
the administration of 5 mL of a saturated sodium bicarbonate solution
(NaHCO3), triggering an increase in gastric pH to values between pH 6 and
pH 7 and subsequently leading to the secretion of stomach acid by the pa-
rietal cells. At the first 8 visits, 125 mL water (control), 37.5/75/150 mg caf-
feine diluted in 125 mL water, or 150 mg caffeine encapsulated in a gelatin
capsule (Coni-Snap size 1; Capsugel) with 125 mL water were administered
5 min after the alkaline challenge (Fig. 1B). A total of 150 mg caffeine in
combination with 30 mg HED or 30 mg HED alone, diluted in 125 mL, were
administered by drinking 5 min after the alkaline solution. At visits 9–11,
three new subjects joined to replace dropouts. There, an empty gelatin
capsule (Coni-Snap size 1; Capsugel), 150 mg caffeine encapsulated, or
150 mg caffeine encapsulated with 30 mg HED were administered with
125 mL water 25 min before the alkaline solution. For exclusive activation of
TAS2Rs in the mouth (delivery protocol 3), the subjects swallowed 125 mL
water and rinsed their mouth with 150 mg caffeine diluted in 125 mL water
without swallowing the caffeine 5 min after swallowing the alkaline solu-
tion. Reacidification time (i.e., time until original pH is reached again after
administration of the alkaline challenge) as well as the slope of the gas-
trogram were analyzed by using Heidelberg Detection System software and
ImageJ software (National Institutes of Health). Delta reacidification time was
calculated by substraction of the reacidification time of the water or empty
capsule control from the reacidification time after the treatment. The slope
was calculated between the point when pH decreases and the point at which
the original pH is reached again.
Organ Bath of Human Stomach Biopsy Specimens. Human stomach was
obtained at surgery for obesity at Homerton University Hospital (London,
United Kingdom) after ethical approval (REC 15/LO/2127) and informed
written consent. Mucosa-free tissue from the fundus region of human
stomachs was dissected parallel to the circular muscle fibers into strips (5–8 ×
15 mm). Strips were tied up and mounted in organ bath chambers that
contained a Krebs solution at 37 °C aerated with 5% CO2 in O2. After 1 h
equilibration, the nerves were excited by electrical field stimulation (EFS) at
200 mA for 0.5 ms; 5 Hz were given for 10 s every 1 min. When there was a
stable response to EFS, a frequency response with 1, 2, 5, 10, 15, and 20 Hz
was generated. After switching back to 5 Hz and reaching a stable signal,
NaHED was applied in a concentration of 1 mM for at least 50 min. Double-
distilled (dd)H2O was used as a vehicle control. Isometric force transducers
(calibrated at 2 g; AD Instruments) and the software AcqKnowledge (Biopac)
detected changes in muscle changes. Data are presented as percent changes
in baseline tension. The number of patients is given as an n value.
Sensory Study. Taste sessions were carried out in the morning hours, and the
13 untrained panel subjects were asked not to consume anything besides
water 30 min before the sensory duo test. The bitter recognition threshold of
the subjects was determined by using a standardized test system startingwith
water and followed by nine solutions with increasing concentrations of caf-
feine, from 25 to 225mg/L. Furthermore, the subjects had to rank the bitterness
of a caffeine solution (150mg/125mL) and a caffeine (150mg/125mL) plus HED
(30 mg/125 mL) solution by sip-and-spit on a scale of 1 (nothing) to 10 (ex-
tremely strong). This dual testwas repeated four times in randomized order and
under colored light. Statistical significance was calculated by Student’s t test
(double-sided, paired).
HGT-1 Cell Culture. The human gastric tumor cell line HGT-1 was obtained
from C. Laboisse (Laboratory of Pathological Anatomy, Nantes, France) and
cultured under standard conditions as described previously (8). Cytotoxicity
of the tested substances and treatment reagents was excluded by MTT test
as described before (8), and cell viability was determined by trypan blue
staining. Tested cells had at least 90% cell viability.
Immunohistochemical Staining of Gastric Tissues. Histological specimens were
obtained from two patients from the Pathologisch-Bakteriologisches Institut,
Sozialmedizinisches Zentrum Ost–Donauspital, Vienna, Austria. The gastric
fundus was derived from a sleeve gastrectomy of a 42-y-old adipose but
otherwise healthy patient. The gastric antrum was derived from a 71-y-old
patient undergoing distal partial gastrectomy for a benign gastrointestinal
stroma tumor. Immunohistochemistry was performed on 5-μm-thick formalin-
fixed, paraffin-embedded whole tissue sections. Slides were processed in the
fully automated staining instrument Benchmark ULTRA by using an ultraView
Universal DAB Detection Kit (VentanaMedical Systems). The following primary
antibodies were applied: TAS2R10 (OSR00158W; Thermo Scientific), 1:750 for
28 min at 37 °C after heat-mediated antigen retrieval using EDTA buffer,
pH 8.0, at 95 °C for 36 min (CC1 buffer; Ventana Medical Systems) and GNAT2
(transducin α-2 chain; AP11077c; Abgent), 1:50 for 28 min at 37 °C after heat-
mediated antigen retrieval using EDTA buffer, pH 8.0, at 95 °C for 64 min
(CC1 buffer; Ventana Medical Systems) and amplification at 95 °C (Amplifi-
cation Kit; Ventana Medical Systems). All counterstaining was performed
with hematoxylin. Blocking experiments to control for unspecific staining
were performed by using the TAS2R10 control peptide (GST00040P; Thermo
Scientific) and GNAT2 antibody blocking peptides (BP11077c; Abgent). For
the TAS2R10 taste receptor, the blocking experiment consisted of the con-
trol peptide, 1:200, incubated together with TAS2R10 antibody, 1:750, for
120 min at 4 °C, and thereafter, incubation of the slide at 37 °C for 28 min.
The GNAT2 antibody blocking peptide, 1:10, was incubated together with
GNAT2 antibody, 1:50, for 120 min at 4 °C, and, thereafter, incubation of the
slide for 28 min at 37 °C. All other steps were performed similarly to the
staining procedure as described earlier.
Immunocytochemical Staining of HGT-1 Cells and HEK-293T-Gα16gust44 Cells.
Transiently transfected HEK-293T-Gα16gust44 cells (TAS2R10 or TAS2R16)
were prepared as described previously (19), and HGT-1 cells were seeded on
coverslips 24 h before the staining procedure. Cells were fixed and stained as
described previously (18) by using anti-HSV (1:15,000; Novagen), anti-
TAS2R10, and anti-GNAT2 antibodies (Immunohistochemical Staining of
Gastric Tissues) for 1 h at room temperature. Specificity of labeling was
ensured as described in Immunohistochemical Staining of Gastric Tissues,
and detection was carried out as described previously (18). Preabsorption of
the anti-TAS2R10 and anti-GNAT2 antibody was performed with the corre-
sponding immunogenic peptide (Immunohistochemical Staining of Gastric
Tissues; Fig. S3). The HSV epitope was detected with anti-mouse antibodies
conjugated with Cy3 (1:2,000; Sigma), biotin-labeled concanavalin A (con A)
with streptavidin Alexa Fluor 633 (1:1,000; Molecular Probes), and TAS2R10
or GNAT2 with Alexa Fluor 488 goat anti-rabbit IgG (1:1,000; Molecular Probes).
Intracellular pH Measurement in HGT-1 Cells Indicating Proton Secretion. In-
tracellular pH, as indicator for proton secretion in HGT-1 cells, was measured
using the pH-sensitive fluorescence dye 1,5 carboxy-seminaphto-rhodafluor
acetoxymethylester (SNARF-1-AM; Life Technologies) as described before
(8, 29). The intracellular proton index (IPX) in the cells was calculated by log2
transformation of the ratio between treated and untreated (i.e., control)
cells. The lower the IPX, the fewer protons are in the cell, indicating a higher
secretory activity in HGT-1 cells.
mRNA Expression of Bitter Taste Receptors in HGT-1 Cells and Human Biopsies
Using RT-qPCR. Total RNA was extracted from HGT-1 cells and two human
biopsy specimens by using the peqGold Total RNA Kit (Peqlab). Quantity and
quality were checked spectrophotometrically. Reverse transcription was
carried out with 2 μg RNA and the High Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific). Real-time PCR was performed with an Applied
Biosystems StepOneplus Real Time PCR system and Fast SYBR Green Master
Mix (Thermo Fisher Scientific). Primers were designed using the National
Center for Biotechnology Information (NCBI) primer designing tool (using
Primer 3 and BLAST; Table S2). Cycling conditions were 20 s/95 °C (activa-
tion), 3 s/95 °C (denaturation), 30 s/60 °C (annealing), and 15 s/67 °C (elon-
gation with fluorescence measurement). The PCR products were verified by
melting curve analysis, agarose gel electrophoresis, and sequence analysis
(Eurofins Genomics). Sequences were checked by using the NCBI BLASTn
tool. Primers showing no product in HGT-1 in at least one of the three
replicates (TAS2Rs 8, 9, 45, and 60) were tested with cDNA derived from a
human tongue biopsy provided by J.-D. Raguse (Charité, Berlin, Germany).
Whereas primers for TAS2Rs 8, 9, and 60 could be verified, TAS2R45 was not
detected. For TAS2R45, high-frequency copy-number variants are known,
and some people do not possess the tested variant of the mRNA for this
gene (44). TAS2R46 could not be detected in the second human biopsy
sample. The open-source software LinRegPCR was used for quantitative PCR
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data analysis. This software enables the calculation of the starting concen-
tration (N0) of each sample, expressed in arbitrary fluorescence units. The
calculated starting concentrations of the TAS2Rs were compared with the
starting concentrations of the acetylcholine receptor (CHRM3), with pre-
viously described primers (8), which is typically expressed in parietal cells on
a functional level.
Generation of TAS2R43 Homozygous KO HGT-1 Cell Line Using CRISPR-Cas9. A
total of 40,000 cells were seeded in a 24-well plate. After approximately 24 h,
cells were transfected with 495 ng GeneArt CRISPR Nuclease (CD4 Vector;
A21175; Invitrogen) containing the gRNA targeting TAS2R43 gene TTTTTT-
GGCAAATGAGGTAC (5′–3′) or, as a control, a scrambled gRNA GTGGACG-
GTCGTGCGCTGT (5′–3′) with no target by using the transfection reagent
Viromer RED (Lipocalyx) according to the manufacturer’s protocol. Trans-
fection efficiency was approximately 25%, verified with a CD4 monoclonal
antibody (07-0403; Invitrogen/Thermo Fisher Scientific) by using a Guava
soft-flow cytometer (Millipore) on the basis that only positively transfected
cells express a CD4 protein. Cells were transferred in a six-well plate to in-
crease cell number. After 3 d, CD4-positive cells (i.e., positively transfected
cells) were enriched by using the Dynabeads CD4 Positive Isolation Kit
(Thermo Fisher Scientific) according to the manufacturer’s protocol. Cells
were analyzed with a Genomic Cleavage detection kit (Thermo Fisher Scien-
tific) according to the manufacturer’s protocol. For genomic cleavage detection,
the following primers were used: forward primer AGACTGCCATTGGGTCAAAGA
(5′–3′) and reverse primer GATGTTGTTGGGGCCTTTGC (5′–3′). The following
temperature protocol was used: 95 °C/10 min, 40 cycles of 95 °C/30s, 58 °C/30 s,
72 °C/30 s, and finally 72 °C for 7 min. A genomic cleavage of approximately
22% was detected. Single cells were isolated by serial dilution of positively
transfected cells into two 96-well plates and observed for colony forming for
2 wk. Total cells of 39 wells in which clearly only one colony formed were
harvested by trypsin/EDTA and first transferred to a 48-well plate, and, after
confluence, to a 12-well plate to increase cell number. From each clone, half of
the cells were frozen and the other half were used to extract DNA with a
PureLink Genomic DNA Mini Kit (Life Technologies) according to the manu-
facturer’s protocol. Before Sanger sequencing by Eurofins Genomics, the DNA
extracts of 20 clones were amplified with AmpliTaqGold 360 Mastermix
(Thermo Fisher Scientific), and PCR was carried out as described earlier for the
genomic cleavage detection. Of 20 clones, 15 showed no deletion, four a
heterozygous deletion, and one a homozygous deletion. Deletion on an
mRNA level was also analyzed by means of Sanger sequencing following
total RNA isolation of the WT, cells transfected with the scrambled gRNA,
and the TAS2R43-KO cells as described earlier (Fig. S7).
Exclusion of Off-Target Effects Using Whole-Genome Sequencing. The quality-
checked DNA was fragmented with a Covaris ultrasonicator. The resulting
DNA fragments were purified, end-blunted, A-tailed, and adaptor-ligated.
The concentration of the libraries was quantified by Bioanalyzer and real-
time PCR. Each library was sequenced with Illumina’s X Ten system with
paired-end 125-bp read length according to the manufacturer’s instructions.
Sequencing-derived raw image files were processed by Illumina’s basecalling
software to yield raw data files in Fastq format. Reads were mapped to the
human reference genome (GRCh37/hg19) using Burroughs–Wheeler Aligner
(v0.7.12). Duplicate reads were removed from mapped data by using Picard
tools (v1.118). SNPs and small insertions and deletions (InDels) were identi-
fied by using the Genome Analysis Toolkit (GATK; v3.3.0). Recommended
best practices for variant analysis were followed, including InDel re-
alignment and base quality score recalibration. The genomic variations were
detected by using GATK’s HaplotypeCaller. Variant quality score recalibra-
tion in GATK was applied to obtain high-confidence variant calls. Copy
number variants were called by using CNVnator (v0.2.7). Structural variants
(SVs) were detected by using Breakdancer or CREST. The SV annotation was
done with SnpEff (v4.0). The University of California, Santa Cruz, LiftOver
tool was used to get the corresponding coordinates from genome build
38 to build 37. Filtering of shared variants was done with GATK’s Select-
Variants tool. Reads mapping to off-target regions were extracted with
SAMtools (v0.1.19).
cAMP Measurements in HGT-1 Cells. cAMP in HGT-1 cells was measured with
the ELISA kit from R&D Systems according to the protocol.
Calcium Imaging Experiments in HEK-293T Cells. Calcium imaging experiments
using HEK-293T cells transiently expressing TAS2Rs and stably expressing the
chimeric G protein subunit Gα16gust44 were essentially done as described
previously (12). Aristolochic acid was dissolved in C1 buffer at 0.03 μM con-
centration and caffeine at 1 mM concentration. Cells were exclusively stimu-
lated with agonists and increasing concentrations of the antagonists in the
concentration range of 0.03–30 μM. For screening which TAS2Rs are activated
or inhibited by HED or ED, they were applied alone as well as coapplied with
suitable TAS2R agonists. Intracellular Ca2+ concentration increases were mea-
sured to monitor changes in TAS2Rs activation upon coapplication of the
putative inhibitors. Potential antagonistic/blocking activity of the compounds
was addressed comparing the signals elicited by cells exclusively stimulated
with the cognate agonists with signals elicited from cells costimulated with
HED or ED in two test concentrations (10 and 100 μM) and the agonists. In-
hibition curves were calculated with SigmaPlot 11 software after correcting
signal responses and normalization to background fluorescence.
Statistical Analysis. Data shown are representative of at least three biological
replicates. All data are expressed as mean ± SEM unless stated otherwise. All
data have been verified for normality distribution, and statistically signifi-
cant differences were considered if the P value was less than 0.05, de-
termined by one-way ANOVA with Dunn’s or Holm–Sídák post hoc test using
SigmaPlot 11.0 software. Correlation analysis according to Spearman was
calculated by SigmaPlot 11.0 software.
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